<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50659">Dronedarone</z:chebi>, an <z:chebi fb="0" ids="2663">amiodarone</z:chebi> analog, was developed to be a safer alternative to <z:chebi fb="0" ids="2663">amiodarone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="50659">Dronedarone</z:chebi> is useful in suppressing <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>/flutter and controlling the ventricular response </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="50659">Dronedarone</z:chebi> reduced cardiovascular hospitalization in the ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of <z:chebi fb="0" ids="50659">dronedarone</z:chebi> 400 mg bid for the prevention of cardiovascular Hospitalization or <z:hpo ids='HP_0011420'>death</z:hpo> from any cause in patiENts with <z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo>/<z:hpo ids='HP_0004749'>atrial flutter</z:hpo>) </plain></SENT>
<SENT sid="3" pm="."><plain>This paper reviews the results of ATHENA, including subsequent sub-analyses of the trial </plain></SENT>
<SENT sid="4" pm="."><plain>These results raise the hypothesis that many of the benefits noted from this trial may be secondary to more than the antiarrhythmic properties of <z:chebi fb="0" ids="50659">dronedarone</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Future studies will clarify the mechanisms of this beneficial effect </plain></SENT>
</text></document>